Android app Apple app link

J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

By Yahoo! Finance   |   6 days ago
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial

Johnson & Johnson (J&J) announced positive results from the Phase III MARIPOSA trial of RYBREVANT and LAZCLUZE combination therapy for NSCLC. The study showed significant improvement in overall survival compared to standard care, with approval in Europe and the US.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.